Lupin receives USFDA approval for generic Topicort Ointment, 0.05%

14 Dec 2016 Evaluate

Lupin has received final approval for its Desoximetasone Ointment USP, 0.05% from the United States Food & Drug Administration (USFDA) to market a generic version of Taro Pharms North’s Topicort Ointment, 0.05%. The product filing is from Lupin’s Pithampur (Indore) manufacturing facility. Topicort Ointment had US sales of $12.1 million, as per IMS MAT September 2016.

Lupin’s Desoximetasone Ointment USP, 0.05% is the AB rated generic equivalent of Taro Pharms North’s Topicort Ointment, 0.05%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Lupin had earlier on December 6, 2016, received final approval for its Desoximetasone Ointment USP, 0.25% from USFDA to market a generic version of Taro Pharmaceuticals, Inc.’s Topicort Ointment, 0.25% having US sales of $14.4 million, as per IMS MAT September 2016.


Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×